Abstract
Tuberous sclerosis complex (TSC) is a complex disease with many different clinical manifestations. Despite the common opinion that TSC is a rare condition, with a mean incidence of 1/6000 live births and a prevalence of 1/20,000, it is increasingly evident that in reality this is not true. Its clinical sequelae span a range of multiple organ systems, in particular the central nervous system, kidneys, skin and lungs. The management of TSC patients is heavily burdensome in terms of time and healthcare costs both for the families and for the healthcare system. Management options include conservative approaches, surgery, pharmacotherapy with mammalian target of rapamycin inhibitors and recently proposed options such as therapy with anti-EGFR antibody and ultrasound-guided percutaneous microwaves. So far, however, no systematically accepted strategy has been found that is both clinically and economically efficient. Thus, decisions are tailored to patients’ characteristics, resource availability and clinical and technical expertise of each single center. This paper reviews the pathophysiology and the clinical (diagnostic-therapeutic) management of TSC.
References
O’Callaghan FJ, Shiell AW, Osborne JP, Martyn CN (1998) Prevalence of tuberous sclerosis estimated by capture–recapture analysis. Lancet 351:1490
O’Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP (2004) An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int 94:853–857
Kristof AS, Li PZ, Major P, Landry JS (2015) Lymphangioleiomyomatosis and tuberous sclerosis complex in Quebec: prevalence and health-care utilization. Chest 148:444–449
Umeoka S et al (2008) Pictorial review of tuberous sclerosis in various organs. Radiographics 28:e32
Schwartz RA, Fernández G, Kotulska K, Jóźwiak S (2007) Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57:189–202
Jones AC et al (1999) Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 64:1305–1315
Dibble CC et al (2012) TBC1D7 is a third subunit of the TSC1–TSC2 complex upstream of mTORC1. Mol Cell 47:535–546
Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK (2001) The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345–355
Jansen FE et al (2008) Cognitive impairment in tuberous sclerosis complex is a multifactorial condition. Neurology 70:916–923
O’Callaghan F (2008) Tuberous sclerosis complex. Paediatr Child Health (Oxford) 18:30–36
Lennert B, Farrelly E, Sacco P, Pira G, Frost M (2013) Resource utilization in children with tuberous sclerosis complex and associated seizures: a retrospective chart review study. J Child Neurol 28:461–469
Vekeman F et al (2015) Kidney involvement in tuberous sclerosis complex: the impact on healthcare resource use and costs. J Med Econ 18:1060–1070
Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823
Carbonara C et al (1994) 9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene. Hum Mol Genet 3:1829–1832
Green AJ, Smith M, Yates JR (1994) Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nat Genet 6:193–196
Henske EP et al (1997) Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151:1639–1647
Crino PB, Aronica E, Baltuch G, Nathanson KL (2010) Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 74:1716–1723
Yates J (1997) Female germline mosaicism in tuberous sclerosis confirmed by molecular genetic analysis. Hum Mol Genet 6:2265–2269
Rose VM et al (1999) Germ-line mosaicism in tuberous sclerosis: how common? Am J Hum Genet 64:986–992
Verhoef S et al (1999) High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 64:1632–1637
Lesma E et al (2009) The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am J Pathol 174:2150–2159
Lesma E et al (2014) TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival. J Cell Mol Med 18:766–779
Hall MN (2008) mTOR-what does it do? Transplant Proc 40:S5–S8
Jülich K, Sahin M (2014) Mechanism-based treatment in tuberous sclerosis complex. Pediatr Neurol 50:290–296
Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13:1259–1268
Tee AR et al (2002) Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99:13571–13576
Curatolo P (2015) Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 52:281–289
Astrinidis A, Henske EP (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24:7475–7481
Wilson C et al (2006) Tsc1 haploinsufficiency without mammalian target of rapamycin activation is sufficient for renal cyst formation in Tsc1+/− mice. Cancer Res 66:7934–7938
Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG (2003) TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147–158
Curatolo P, Moavero R, de Vries PJ (2015) Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol 14:733–745
Kingswood C et al (2016) The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Eur J Paediatr Neurol 20:296–308
Kohrman MH (2012) Emerging treatments in the management of tuberous sclerosis complex. Pediatr Neurol 46:267–275
Inoue Y et al (1998) CT and MR imaging of cerebral tuberous sclerosis. Brain Dev 20:209–221
Kotulska K et al (2014) Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Childs Nerv Syst 30:2037–2042
Jóźwiak S, Mandera M, Młynarski W (2015) Natural history and current treatment options for subependymal giant cell astrocytoma in tuberous sclerosis complex. Semin Pediatr Neurol 22:274–281
Krishnan A, Kaza RK, Vummidi DR (2016) Cross-sectional imaging review of tuberous sclerosis. Radiol Clin N Am 54:423–440
Webb DW, Fryer AE, Osborne JP (1996) Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 38:146–155
Jóźwiak S et al (2011) Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 15:424–431
Józ°wiak S, Schwartz RA, Janniger CK, Michałowicz R, Chmielik J (1998) Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 37:911–917
Webb DW, Clarke A, Fryer A, Osborne JP (1996) The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol 135:1–5
Tonekaboni SH et al (2012) Clinical and para clinical manifestations of tuberous sclerosis: a cross sectional study on 81 pediatric patients. Iran J Child Neurol 6:25–31
Bell SD, MacDonald DM (1985) The prevalence of cafe-au-lait patches in tuberous sclerosis. Clin Exp Dermatol 10:562–565
Moir LM, Lymphangioleiomyomatosis (2016) Current understanding and potential treatments. Pharmacol Ther 158:114–124
Taveira-DaSilva AM, Moss J (2015) Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis. Clin Epidemiol 7:249–257
Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 97:6085–6090
Axt-Fliedner R et al (2001) Prenatal diagnosis of cerebral lesions and multiple intracardiac rhabdomyomas in a fetus with tuberous sclerosis. J Ultrasound Med 20:63–67
Lendvay TS, Marshall FF (2003) The tuberous sclerosis complex and its highly variable manifestations. J Urol 169:1635–1642
Jost CJ et al (2001) Aortic aneurysms in children and young adults with tuberous sclerosis: report of two cases and review of the literature. J Vasc Surg 33:639–642
Stillwell TJ, Gomez MR, Kelalis PP (1987) Renal lesions in tuberous sclerosis. J Urol 138:477–481
Webb DW, Kabala J, Osborne JP (1994) A population study of renal disease in patients with tuberous sclerosis. Br J Urol 74:151–154
O’Hagan AR, Ellsworth R, Secic M, Rothner AD, Brouhard BH (1996) Renal manifestations of tuberous sclerosis complex. Clin Pediatr (Phila) 35:483–489
Shepherd CW, Gomez MR, Lie JT, Crowson CS (1991) Causes of death in patients with tuberous sclerosis. Mayo Clin Proc 66:792–796
Cook JA, Oliver K, Mueller RF, Sampson J (1996) A cross sectional study of renal involvement in tuberous sclerosis. J Med Genet 33:480–484
Rakowski SK et al (2006) Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors. Kidney Int 70:1777–1782
Halpenny D, Snow A, McNeill G, Torreggiani WC (2010) The radiological diagnosis and treatment of renal angiomyolipoma—current status. Clin Radiol 65:99–108
Ewalt DH, Sheffield E, Sparagana SP, Delgado MR, Roach ES (1998) Renal lesion growth in children with tuberous sclerosis complex. J Urol 160:141–145
Koo KC et al (2010) Trends of presentation and clinical outcome of treated renal angiomyolipoma. Yonsei Med J 51:728–734
Yamakado K et al (2002) Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 225:78–82
Kapoor A et al (2016) Evolving strategies in the treatment of tuberous sclerosis complex-associated angiomyolipomas (TSC-AML). Urology 89:19–26
Neumann HP et al (1995) Tuberous sclerosis complex with end-stage renal failure. Nephrol Dial Transplant 10:349–353
Schillinger F, Montagnac R (1996) Chronic renal failure and its treatment in tuberous sclerosis. Nephrol Dial Transplant 11:481–485
Clarke A, Hancock E, Kingswood C, Osborne JP (1999) End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant 14:988–991
Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49:243–254 (2013)
Krueger DA, Northrup H Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol 49:255–265 (2013)
Granata S et al (2016) Sirolimus and everolimus pathway: reviewing candidate genes influencing their intracellular effects. Int J Mol Sci 17:735
Bissler JJ et al (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381:817–824
Curatolo P, Moavero R (2012) mTOR inhibitors in tuberous sclerosis complex. Curr Neuropharmacol 10:404–415
Dabora SL et al (2011) Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 6:e23379
Davies DM et al (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17:4071–4081
Krueger DA et al (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811
Franz DN et al (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59:490–498
Tarasewicz A et al (2009) Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc 41:3577–3582
Sasongko TH, Ismail NFD, Nik Abdul Malik NMA, Zabidi-Hussin ZAMH (2015) Rapamycin and its analogues (rapalogs) for tuberous sclerosis complex-associated tumors: a systematic review on non-randomized studies using meta-analysis. Orphanet J Rare Dis 10:95
Trelinska J et al (2015) Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. Pediatr Blood Cancer 62:616–621
Cappellano AM et al (2013) Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex. Childs Nerv Syst 29:2301–2305
Major P (2011) Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex. Aging (Albany NY) 3:189–191
Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125–132
Krueger DA et al (2013) Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology 80:574–580
French JA et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388:2153–2163
Pascual J, Marcén R, Ortuño J (2005) Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 79:S80–S84
Goyer I, Dahdah N, Major P (2015) Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol 52:450–453
Sadowski K, Kotulska K, Jóźwiak S (2016) Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep 68:536–542
Kaplan B, Qazi Y, Wellen JR (2014) Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev (Orlando) 28:126–133
Kalogirou E-M, Tosios KI, Piperi EP, Sklavounou A (2015) mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. Oral Surg Oral Med Oral Pathol Oral Radiol 119:e13–e19
Sasaoka T et al (2010) Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients. Transplant Proc 42:3700–3703
Willemsen AECAB et al (2014) Diagnostic challenges of respiratory adverse events during everolimus treatment. Target Oncol 9:287–291
Alexandru S et al (2008) Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 23:3353–3355
Rodríguez-Moreno A et al (2009) Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 41:2163–2165
Teplinsky E et al (2013) Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat 141:167–172
Atzori L, Conti B, Zucca M, Pau M (2015) Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients. J Eur Acad Dermatol Venereol 29:1626–1630
Trelinska J et al (2015) Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anticancer Drugs 26:437–442
Diekmann F, Andrés A, Oppenheimer F (2012) mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 26:27–29
Stallone G et al (2011) Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91:997–1004
Vollenbröker B et al (2009) mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Ren Physiol 296:F418–F426
Eijkemans MJC et al (2015) Long-term follow-up assessing renal angiomyolipoma treatment patterns, morbidity, and mortality: an observational study in tuberous sclerosis complex patients in the Netherlands. Am J Kidney Dis 66:638–645
Chatziioannou A et al (2012) Transcatheter arterial embolization as therapy of renal angiomyolipomas: the evolution in 15 years of experience. Eur J Radiol 81:2308–2312
De Pasquale V et al (2013) Selective arterial embolization of giant renal tuberous sclerosis. Indian J Pediatr 80:263–265
Ewalt DH et al (2005) Long-term outcome of transcatheter embolization of renal angiomyolipomas due to tuberous sclerosis complex. J Urol 174:1764–1766
Bardin F et al (2017) Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction. Quant Imaging Med Surg 7:8–23
Wang C et al (2017) Transarterial embolization for renal angiomyolipomas: a single centre experience in 79 patients. J Int Med Res 45:706–713
Cristescu M et al (2016) Percutaneous microwave ablation of renal angiomyolipomas. Cardiovasc Interv Radiol 39:433–440
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical approval
Ethical committee of San Paolo Hospital approved data analysis of TSC patients.
Research involving human participants and/or animals
This article does not contain any studies with human participants performed by any of the authors.
Informed consent
Not available.
Rights and permissions
About this article
Cite this article
Volpi, A., Sala, G., Lesma, E. et al. Tuberous sclerosis complex: new insights into clinical and therapeutic approach. J Nephrol 32, 355–363 (2019). https://doi.org/10.1007/s40620-018-0547-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-018-0547-6